CD22 and acute lymphoblastic leukemia: The first such trial (AMELIA; NCT03289455) included 15 children with r/r B-ALL, and utilized a second generation, autologous CAR T-cell product (AUTO3) expressing both anti-CD19 and anti-CD22 CARs, while also including a tumor necrosis factor receptor (TNFR) co-stimulatory domain.110